irinotecan has been researched along with carboplatin in 203 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (3.94) | 18.2507 |
| 2000's | 102 (50.25) | 29.6817 |
| 2010's | 83 (40.89) | 24.3611 |
| 2020's | 10 (4.93) | 2.80 |
| Authors | Studies |
|---|---|
| Hata, K; Higuchi, M; Kajino, T; Shibata, N | 1 |
| Ariyoshi, Y; Hotta, T; Kobayashi, T; Ogura, M; Ohashi, Y; Ohnishi, K; Ohno, R; Saito, H; Shirakawa, S; Takeyama, K; Tobinai, K | 1 |
| Kojima, Y; Kotake, T; Maeda, O; Miki, T; Nonomura, N; Okuyama, A; Saiki, S; Sawada, M | 1 |
| Natale, RB | 1 |
| Kunikane, H; Kunitoh, H; Nagatomo, A; Okamoto, H; Watanabe, K | 1 |
| Armand, JP; Couteau, C | 1 |
| Fujiwara, Y; Isobe, T; Katoh, O; Kurata, T; Miyazaki, M; Oguri, T; Ohashi, N; Takahashi, T; Yamakido, M; Yokozaki, M | 1 |
| Fukuda, M; Kawabata, S; Kinoshita, A; Kohno, S; Nakatomi, K; Noguchi, Y; Oka, M; Soda, H; Takatani, H; Terashi, K; Tsukamoto, K; Tsurutani, J | 1 |
| Fujioka, M; Hashimoto, D; Idezuki, Y; Inokuma, S; Ishida, H; Ishizuka, N; Murata, N; Nakada, H; Odaka, A; Ohsawa, T; Okita, H; Suzuki, T; Takahama, T; Takeuchi, I; Yamada, H; Yokoyama, M | 1 |
| Sandler, A | 1 |
| Israel, VP; Miller, L; Natale, RB; Sandler, A; Socinski, M | 1 |
| Rushing, DA | 1 |
| Fujita, A; Sekine, K; Tagaki, S; Takabatake, H | 1 |
| Elfring, GL; Hanover, CK; Israel, VK; Locker, PK; Miller, LL; Natale, RB; Pirotta, N; Sandler, AB; Socinski, MA | 1 |
| Bonomi, P; Shirazi, W | 1 |
| Belani, CP; Calvo, AR | 1 |
| Aiba, K; Akaza, H; Hoctin-Boes, G; Isonishi, S; Kawai, K; Konishi, T; Mikami, O; Miki, T; Noguchi, S; Ohashi, Y; Saeki, T; Saijo, N; Smith, M; Sone, S; Stribling, D; Tsukagoshi, S; Tsuruo, T | 1 |
| Arimoto, Y; Hayashi, S; Komura, H; Kunishige, I; Okuno, Y; Otsuki, Y; Shimoya, K | 1 |
| Murren, JR | 1 |
| Fukuoka, M; Negoro, S; Nitta, T; Takeda, K; Takifuji, N; Terakawa, K; Yoshimura, N | 1 |
| Boccieri, MG; Bruschi, G; Lo Re, G; Saracchini, S; Toffoli, G; Tumolo, S | 1 |
| Caffo, O | 1 |
| Ando, M; Ando, Y; Hasegawa, Y; Ikeda, T; Minami, H; Saka, H; Sakai, S; Sato, M; Sekido, Y; Shimokata, K; Watanabe, A; Yamamoto, M | 1 |
| Aiba, K; Akaza, H; Blackledge, G; Boku, N; Ikeda, T; Isonishi, S; Kato, M; Kawai, K; Mikami, O; Ohashi, Y; Saeki, T; Saijo, N; Sone, S; Stribling, D; Tsukagoshi, S; Tsuruo, T | 1 |
| Misset, JL | 1 |
| Giacchetti, S | 1 |
| Berg, S; Bernstein, M; Blaney, SM; Cherrick, I; Kuttesch, N; Murry, DJ; Salama, V | 1 |
| Kato, H; Tsuboi, M | 1 |
| Athanassiou, A; Bountouroglou, N; Glotsos, J; Karvounis, N; Kouloubinis, A; Pectasides, D; Visvikis, A; Ziras, N | 1 |
| Fujita, A; Hoshino, H; Ohkubo, T; Sekine, K; Tagaki, S; Takabatake, H | 1 |
| Fukuda, H; Fukuoka, M; Kudoh, S; Nakagawa, K; Negoro, S; Nishimura, Y; Takeda, K; Tanaka, M; Yamada, M; Yamamoto, N | 1 |
| Atagi, S; Furuse, K; Hosoe, S; Kawaguchi, T; Kawahara, M; Naka, N; Ogawara, M; Okishio, K; Takemoto, Y; Tsuchiyama, T; Ueno, K | 1 |
| Antonellini, A; Elfring, GL; Gillenwater, HH; Israel, VK; Locker, PK; Miller, LL; Natale, RB; Sandler, AB; Socinski, MA | 1 |
| Kawano, Y; Miyakawa, I; Narahara, H; Nasu, K; Takai, N; Utsunomiya, H | 1 |
| Negoro, S; Takeda, K; Takifuji, N; Terakawa, K; Uejima, H; Yoshimura, N | 1 |
| Baldwin, AS; Cusack, JC; Ewend, MG; Weaver, KD; Yeyeodu, S | 1 |
| Adachi, M; Ando, K; Hirose, T; Horichi, N; Hosaka, T; Ishida, H; Noguchi, H; Ogura, K; Ohmori, T | 1 |
| Belinson, J; Markman, M; Rose, P; Webster, K; Zanotti, K | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD; Jones, SF; Kuzur, ME; Miranda, FT; Raefsky, EA; White, MB; Willcutt, NT; Yardley, DA | 1 |
| Gandara, DR; Houston, J; Lara, PN; Lau, DH; Lauder, J; Meyers, FJ; Tanaka, M; Wang, SE; Wild, CA | 1 |
| Faust, J; Govindan, R; Mc Leod, H; Read, W | 1 |
| Aghajanian, C; Dizon, DS; Hensley, M; Hummer, A; Leitao, MM; Sabbatini, P; Spriggs, DR; Venkatraman, E | 1 |
| Hiroi, M; Isobe, K; Kimura, K; Ryo, H; Sano, G; Sugino, K; Toyama, K; Yamada, H | 1 |
| Belinson, J; Escobar, PF; Markman, M; Rose, P; Webster, K; Zanotti, K | 1 |
| Inciūra, A; Juozaityte, E | 1 |
| Maeda, K; Okamura, S; Shibuya, T; Suzumiya, J; Suzushima, H; Tamura, K; Utsunomiya, A | 1 |
| Isonishi, S; Niimi, S; Ochiai, K; Sasaki, H; Tanaka, T; Yasuda, M | 1 |
| Hütter, G; Keilholz, U; Krebs, P; Schmittel, A; Schulze, K; Thiel, E | 1 |
| Fukuda, M; Inoue, Y; Kasai, T; Kinoshita, A; Kohno, S; Kuba, M; Nagashima, S; Nakamura, Y; Oka, M; Soda, H; Soejima, Y; Takatani, H; Tsurutani, J | 1 |
| Ajani, JA; Bresalier, R; Correa, AM; Erasmus, JJ; Komaki, R; Macapinlac, H; Maish, M; Munden, RF; Putnam, JB; Rice, D; Roth, JA; Smythe, WR; Swisher, SG; Vaporciyan, AA; Walsh, GL; Wu, TT | 1 |
| Detterbeck, FC; Fraser, R; Halle, JS; Hensing, TA; Limentani, SA; Mears, A; Moore, DT; Morris, DE; Rivera, MP; Rosenman, JG; Socinski, MA; Tynan, M | 1 |
| Terauchi, F | 1 |
| Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Hermann, R; Litchy, S; Morrissey, LH; Rodriguez, GI; Shaffer, DW; Yardley, DA | 1 |
| Adachi, M; Horichi, N; Ichikawa, I; Imai, T; Kashiwabara, Y; Kiuchi, Y; Kogo, M; Koichi, K; Murayama, J; Saito, Y | 1 |
| Aoki, Y; Fujita, K; Kurata, H; Tanaka, K; Watanabe, M | 1 |
| Sugiyama, T | 1 |
| Govindan, R; McLeod, H; Read, W | 1 |
| Dumontet, C; Sève, P | 1 |
| Brener, J; Chaitchik, S; Czerniak, A; Hayat, H; Schachter, P; Shimonov, M | 1 |
| Ieki, R; Iguchi, M; Kato, T; Okamura, T; Ota, T; Saito, E; Shibuya, M; Yuasa, K | 1 |
| David, A; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Moeneclaey, N | 1 |
| Lopes, G; Rocha Lima, CM | 1 |
| Fujiwara, Y; Kasamatsu, T; Katsumata, N; Tsunematsu, R; Yamada, T; Yamamoto, N; Yonemori, K | 1 |
| Fujimoto, K; Harada, T; Watanabe, K | 1 |
| Kaneda, T; Narita, Y; Suzuki, A; Takahashi, N; Tsunematsu, K | 1 |
| Greco, FA; Spigel, DR | 1 |
| Chan, S; Clamp, AR; Cruickshank, D; Hindley, A; Jayson, GC; Ledermann, J; Mäenpää, J; Sorbe, B; Vasey, P; Welch, R; Wilkinson, PM | 1 |
| Fischer von Weikersthal, L; Hortig, P; Keilholz, U; Martus, P; Reeb, M; Schmittel, A; Schulze, K; Sebastian, M; Thiel, E | 1 |
| Adami, G; Belvedere, O; Ceschia, T; Fasola, G; Grossi, F; Meduri, S; Recchia, L; Rizzato, S; Rossetto, C; Sacco, C; Sibau, A; Spizzo, R; Tumolo, S; Vigevani, E | 1 |
| Fukuda, M; Kinoshita, A; Kohno, S; Kuba, M; Nagashima, S; Nakamura, Y; Oka, M; Soda, H; Takatani, H; Tsurutani, J | 1 |
| Cloughesy, TF; Lai, A; Mischel, P; Nghiemphu, P; Pope, WB | 1 |
| Kobayashi, K; Sutani, A | 1 |
| Hida, N; Kunikane, H; Naoki, K; Narita, Y; Okamoto, H; Watanabe, K | 1 |
| Brunetto, AL; Castro, CG; Cruz, LB; Rech, A; Ribeiro, AS; Rosa, LG | 1 |
| Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Kobayashi, H; Mano, H; Tsunoda, S | 1 |
| Katakami, N | 1 |
| Crawford, J; Dunphy, F; Garst, J; Herndon, JE; Kelley, MJ; Riedel, RF | 1 |
| Chang, J; Cho, BC; Choi, HJ; Chung, KY; Kim, DJ; Kim, JH; Kim, SK; Lee, CG; Moon, YW; Shin, SJ; Sohn, JH | 1 |
| Ariyoshi, Y; Fukuoka, M; Kubota, K; Nakagawa, K; Negoro, S; Nishiwaki, Y; Ohashi, Y; Ohe, Y; Saijo, N; Tamura, T | 1 |
| Antonia, S; Chiappori, A; de Lima Lopes, G; Haura, E; Langevin, M; Lush, R; Rocha-Lima, CM; Simon, G; Sullivan, D | 1 |
| Ono, A; Yamamoto, N | 1 |
| Atkins, JN; Bearden, JD; Case, D; Giguere, JK; Miller, AA | 1 |
| Cummings, K; Gao, F; Govindan, R; Hennenfent, KL; Marsh, S; McLeod, HL; Pillot, GA; Read, WL; Viswanathan, A | 1 |
| Andritzky, B; Bokemeyer, C; Burkholder, I; Dürk, H; Edler, L; Elbers, M; Engel-Riedel, W; Fischer, J; Görn, M; Gütz, S; Hossfeld, DK; Kortsik, C; Krüll, A; Laack, E; Meissner, C; Müller, T; Schuch, G; Thöm, I | 1 |
| Jobo, T | 1 |
| Kigawa, J; Kikuchi, Y; Kuzuya, K; Moriya, T; Sagae, S; Sugiyama, T; Suzuki, M; Takano, M; Takeuchi, S; Tsuda, H; Udagawa, Y; Yaegashi, N | 1 |
| Burris, HA; Grapski, R; Greco, FA; Hainsworth, JD; Mallidi, PV; Meng, C; Schreeder, M; Simons, L; Spigel, DR; Yardley, DA | 1 |
| Seto, T | 1 |
| Baker, SD; Chatelut, E; Mathijssen, RH; Rowinsky, EK; Sparreboom, A; Verweij, J; Wolff, AC | 1 |
| Fujiwara, S; Ino, K; Kajiyama, H; Kato, S; Kikkawa, F; Nakamura, S; Nawa, A; Shibata, K; Suzuki, K | 1 |
| Choong, NW; Ferguson, MK; Haraf, DJ; Hoffman, PC; Kasza, K; Krauss, SA; Mauer, AM; Rudin, CM; Szeto, L; Tothy, PK; Vokes, EE | 1 |
| Baba, M; Hayashi, N; Kakimoto, Y; Koshiishi, H; Koshiishi, Y; Minami, T; Okamura, T; Takahashi, E; Yasui, T | 1 |
| An, CH; Cho, EK; Choi, SJ; Jeong, SH; Kim, Y; Kyung, SY; Lee, JH; Lee, JI; Lee, SP; Park, J; Park, JW; Park, SH; Shin, DB | 1 |
| Chen, A; Chen, G; Fehrenbacher, L; Gandara, D; Huynh, M; Lau, D | 1 |
| Duh, MS; Lefebvre, P; Neary, M; Reynolds Weiner, J; Skarin, AT | 1 |
| Halle, JS; Hayes, DN; Lee, CB; Moore, DT; Morris, DE; Rivera, MP; Rosenman, JG; Socinski, MA; Stinchcombe, TE | 1 |
| Alami, N; Jerome, L; Leyland-Jones, B; Page, V; Paterson, J; Shiry, L; Yu, Q | 1 |
| Hirose, S; Hojo, T; Ikeuchi, S; Isobe, Y; Kinoshita, T; Kubochi, K; Matsumoto, S; Sadako, AT; Shien, T; Terada, K | 1 |
| Armstrong, MB; Castle, VP; Mody, R; Opipari, AW; Schumacher, KR; Yanik, GA | 1 |
| Aasebø, U; Bergman, B; Bremnes, R; Ek, L; Fluge, S; Hermes, A; Sederholm, C; Sörenson, S; Sundstrøm, S; Thaning, L; Vilsvik, J | 1 |
| Ando, M; Arioka, H; Fujiwara, Y; Hirakawa, A; Hirata, T; Katsumata, N; Kouno, T; Matsumoto, K; Shimizu, C; Tamura, K; Yamanaka, Y; Yonemori, K; Yunokawa, M | 1 |
| Angiolillo, A; Cohen, MB; Gorlick, R; Jakacki, R; Levy, AS; Meyers, PA; Ringuette, SN; Wexler, LH | 1 |
| Chen, G; Fehrenbacher, L; Gandara, D; Goldstein, D; Huynh, M; Lara, PN; Lau, D; Russin, M; West, H; Yavorkovsky, LL | 1 |
| Fujimoto, T; Koshiji, M; Nambu, Y; Yamamoto, N | 1 |
| Fujii, T; Fukuda, H; Kunikane, H; Kunitoh, H; Mori, K; Okamoto, H; Saijo, N; Tamura, T; Watanabe, K; Yokoyama, A | 1 |
| Glisson, BS; Johnson, FM | 1 |
| Aguero, EG; Garrett-Mayer, E; Reed, CE; Ruppert, BN; Sharma, AK; Sherman, CA; Shirai, K; Wahlquist, AE; Watkins, JM | 1 |
| Izumi, K; Mouri, H; Ohtsubo, K; Watanabe, H; Yamada, T; Yamashita, K; Yano, S; Yasumoto, K; Zen, Y | 1 |
| Choi, K; Rineer, J; Sanmugarajah, J | 1 |
| Hida, T; Kimura, T; Saga, K | 1 |
| Burris, HA; Farley, C; Greco, FA; Hainsworth, JD; Murphy, PB; Saez, RA; Spigel, DR; Yardley, DA; Zubkus, JD | 1 |
| Adachi, M; Hirose, T; Nakamura, A; Ohnishi, T; Okuda, K; Yamaoka, T; Yashiki, C | 1 |
| Aoki, D; Inaba, N; Noda, K; Ochiai, K; Saito, T; Sugiyama, T; Takahashi, F; Takakura, S; Takano, M | 1 |
| Cho, EK; Jung, SH; Kim, YS; Kyung, SY; Lee, JH; Lee, SP; Park, J; Park, JW; Park, SH; Shin, DB; Sym, SJ | 1 |
| Aizawa, H; Ichiki, M; Inoue, Y; Nakamura, M; Saitsu, H; Sakata, S; Tokito, T; Wada, Y | 1 |
| Bastos, BR; Gomez, J; Hatoum, GF; Lopes, G; Raez, LE; Santos, ES; Takita, C; Tolba, K; Walker, GR | 1 |
| Charpidou, A; Gkiozos, I; Makrilia, N; Stratakos, G; Syrigos, K; Tsagouli, S; Tsimpoukis, S; Vassias, A | 1 |
| Chu, Z; Huang, L; Huang, R; Jiang, J; Liang, X; Zhan, Q; Zhou, X | 1 |
| Chiba, Y; Fukuoka, M; Hida, T; Imamura, F; Iwamoto, Y; Katakami, N; Kawahara, M; Kudo, S; Nakagawa, K; Nishimura, Y; Saka, H; Satouchi, M; Sawa, T; Semba, H; Seto, T; Takeda, K; Tsujino, K; Uejima, H; Yamamoto, N; Yokota, S | 1 |
| Briasoulis, E; Fountzilas, G; Golfinopoulos, V; Karina, M; Papakostas, P; Pavlidis, N | 1 |
| Dosa, E; Kraemer, DF; Neuwelt, EA; Thompson, EM | 1 |
| Cantor, A; Miley, D; Reddy, V; Robert, F; Rossman, J | 1 |
| Ikeda, S; Inagaki, M; Suzuki, K; Takabe, K | 1 |
| Chen, C; Damek, D; Fields, EC; Gaspar, LE; Kavanagh, BD; Lillehei, K; Liu, AK; Waziri, A | 1 |
| Cheung, NK; Kramer, K; Kushner, BH; Modak, S | 1 |
| Huang, XE; Jiang, Y; Li, Y; Xiang, J; Yan, PW | 1 |
| Kumabe, T; Niizuma, H; Osawa, S; Saito, R; Sonoda, Y; Tominaga, T; Watanabe, M | 1 |
| Binder, D; Caca, K; Eberhardt, WE; Fischer von Weikersthal, L; Fischer, B; Fischer, JR; Gauler, TC; Hortig, P; Kaufmann, C; Keilholz, U; Link, H; Martus, P; Schmittel, A; Sebastian, M | 1 |
| Adachi, M; Hirose, T; Kusumoto, S; Murata, Y; Nakashima, M; Ohmori, T; Okuda, K; Shirai, T; Sugiyama, T; Yamaoka, T | 1 |
| Ando, M; Fujiwara, Y; Hirata, T; Katsumata, N; Ono, M; Shimizu, C; Tamura, K; Yamamoto, H; Yonemori, K | 1 |
| Coan, A; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Peters, KB; Reardon, DA; Sampson, JH; Threatt, S; Vredenburgh, JJ | 1 |
| Amin, NP; Camidge, DR; Gaspar, LE; Kavanagh, B; Miften, M; Raben, D; Rochford, N; Thornton, D | 1 |
| Devore, RF; Horn, L; Johnson, D; Laskin, J; Sandler, A; Shyr, Y; Wolff, S; Zhao, Z | 1 |
| Allen, PJ; Brady, MS; Busam, KJ; Chou, JF; Coit, DG; Fields, RC; Kraus, DH; Panageas, KS; Pulitzer, MP | 1 |
| Bulusu, A; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Peters, KB; Reardon, DA; Sampson, JH; Threatt, S; Vredenburgh, JJ | 1 |
| Buhr, HJ; Fusi, A; Hotz, B; Hotz, HG; Keilholz, U | 1 |
| Ota, T; Takeshima, N; Takizawa, K | 1 |
| Cai, JF; Chen, B; Lu, HY; Ma, SL; Su, D; Sun, WY; Wang, Z; Zhang, YP; Zheng, YQ | 1 |
| Jin, S; Shao, N; Zhu, W | 1 |
| Cho, YJ; Duk Lee, J; Go, SI; Hwang, YS; Jeong, YY; Kim, DC; Kim, HC; Ko, GH; Lee, GW; Lee, JH; Lee, JS; Oh, S; Yang, JW | 1 |
| Iitsuka, C; Iwase, H; Nomura, H; Omatsu, K; Sakamoto, K; Takada, T; Takeshima, N; Takizawa, K | 1 |
| Daimon, T; Furuse, K; Kawahara, M; Mio, T; Okishio, K; Yanagihara, K; Yoshioka, H | 1 |
| Iyoda, A; Jiang, SX; Kageyama, T; Masuda, N; Matsumoto, T; Nagashio, R; Ryuge, S; Saegusa, M; Sato, Y; Satoh, Y | 1 |
| Burris, HA; Eakle, JF; Greco, FA; Hainsworth, JD; Lubiner, ET; Quinn, R; Rubin, MS; Shipley, D; Spigel, DR; Thompson, DS | 1 |
| Dharmarajan, KV; Wexler, LH; Wolden, SL | 1 |
| Furuya, K; Goto, T; Kato, M; Kita, T; Kudoh, K; Miyamoto, M; Sasaki, N; Takano, M; Watanabe, A; Yoshikawa, T | 1 |
| Bradbury, J; Cave, J; Crabb, SJ; Johnson, PW; Muthuramalingam, SR; Nolan, L; Ottensmeier, C; Selman, D | 1 |
| Ando, M; Gemma, A; Hino, M; Kobayashi, K; Kosaihira, S; Minegishi, Y; Miyanaga, A; Mizutani, H; Nomura, K; Noro, R; Okano, T; Seike, M; Yoshimura, A | 1 |
| Basu, EM; Cheung, NK; Kramer, K; Kushner, BH; Modak, S; Roberts, SS | 1 |
| Demolin, G; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Moeneclaey, N | 1 |
| Ansari, RH; Atkins, JN; Bogart, JA; Green, MR; Hodgson, LD; Kelley, MJ; Pang, H; Vokes, EE | 1 |
| Akamatsu, H; Endo, M; Kenmotsu, H; Murakami, H; Naito, T; Nakajima, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tsuya, A; Wakuda, K; Yamamoto, N | 1 |
| Arakawa, A; Itani, Y; Ito, K; Kawaguchi, R; Shiozaki, T; Tabata, T; Takeuchi, S; Toyoda, S; Tsubamoto, H | 1 |
| Enomoto, T; Fujita, M; Kimura, T; Kobayashi, E; Matsuzaki, S; Tsutsui, T; Ueda, Y; Yoshino, K | 1 |
| Choi, DR; Choi, HC; Kim, B; Kim, HS; Kim, JH; Kwon, JH | 1 |
| Fujiwara, K; Katakami, N; Kitao, A; Matsumoto, K; Minami, H; Morita, S; Negoro, S; Shibata, N; Tanioka, M; Yamaguchi, S | 1 |
| Enomoto, T; Fujita, M; Kimura, T; Miyatake, T; Nagamatsu, M; Nishio, Y; Tsutsui, T; Ueda, Y; Yamasaki, M; Yoshino, K | 1 |
| Hida, N; Horiike, A; Ishii, M; Kenmotsu, H; Misumi, Y; Murakami, H; Nishio, M; Ohyanagi, F; Okamoto, H; Shimokawa, T; Takahashi, T; Yamamoto, N | 1 |
| Chohnabayashi, N; Ishikawa, G; Jinta, T; Kitamura, A; Mochizuki, S; Nishimura, N; Suzuki, K; Tomishima, Y; Yamano, Y | 1 |
| Bloomfield, A; Dorton, R; Guan, J; Leamon, CP; Nelson, M; Reddy, JA; Vetzel, M | 1 |
| Aoyama, T; Hamano, T; Hashimura, T; Kawai, J; Kimura, H; Uegaki, M | 1 |
| Arce-Lara, C; Kelley, MJ; Santana-Davila, R; Szabo, A; Whittle, J; Williams, CD | 1 |
| Boku, N; Furuse, J; Ishido, K; Kasuga, A; Machida, N; Morizane, C; Nishina, T; Okusaka, T; Sudo, K; Takahashi, H; Tobimatsu, K; Yamaguchi, T | 1 |
| Kadowaki, M; Kohno, K; Kondo, S; Kubota, A; Okamura, S; Takase, K; Takeshita, M; Tanimoto, K; Yamasaki, S | 1 |
| Cao, J; Huang, XE; Qian, ZY; Shi, L; Wu, XY; Xu, X | 1 |
| Asamura, H; Fujiwara, Y; Horinouchi, H; Kanda, S; Kitazono, S; Mizugaki, H; Nokihara, H; Tamura, T; Tanaka, A; Tsuta, K; Yagishita, S; Yamamoto, N | 1 |
| Cho, H; Kim, JH; Kim, S; Kim, SW; Kim, YT; Lee, M; Nam, EJ | 1 |
| Eba, J; Misumi, Y; Nakamura, K; Ohe, Y; Okamoto, H; Shibata, T; Shimokawa, T; Yamamoto, N | 1 |
| Calkins, SM; Cinar, P; Kelley, RK; Venook, AP | 1 |
| Kamei, T; Miwa, I; Nakamura, Y; Sakamoto, Y; Shinagawa, M | 1 |
| Harada, M; Inoue, A; Ishida, T; Kinoshita, I; Maemondo, M; Mori, Y; Morikawa, N; Nakagawa, T; Nukiwa, T; Oizumi, S; Saito, R; Sugawara, S; Suzuki, T; Taima, K; Watanabe, H | 1 |
| Inoue, A; Ishimoto, O; Maemondo, M; Nukiwa, T; Sugawara, S | 1 |
| Dartigues, P | 1 |
| Chang, GJ; Crane, CH; Das, P; Feig, BW; Krishnan, S; Minsky, BD; Rashid, A; Skibber, JM; Voong, KR; Wolff, RA; Yao, JC | 1 |
| Allendorf, DJ; Bordoni, RE; Dixon, PM; Grant, SC; Jerome, ML; Miley, DK; Reddy, VB; Robert, F; Saleh, MN; Singh, KP | 1 |
| Hur, GY; Kang, EJ; Kang, KH; Kim, JS; Lee, SY; Min, KH; Oh, SC; Seo, JH; Shim, JJ | 1 |
| Blumenthal, DT; Bokstein, F; Mendel, L | 1 |
| Chen, L; Chen, Y; Feng, X; Peng, L; Wang, J; Zhong, D | 1 |
| Boumber, Y; Cai, KQ; Deneka, A; Duncan, JS; Duncan, KE; Egleston, BL; Gaponova, AV; Golemis, EA; Khazak, V; Kopp, MC; Kudinov, AE; Nikonova, AS; Ogawa, LS; Proia, DA; Skobeleva, N | 1 |
| Alexandre, J; Aoki, D; Aotani, E; Enomoto, T; Fujiwara, K; Green, J; Hamano, T; Isonishi, S; Kato, K; Kim, BG; Kim, JW; Mikami, M; Nishino, K; Nomura, H; Okamoto, A; Pignata, S; Sugiyama, T; Suzuki, N; Tanabe, H; Terao, Y; Terauchi, F; Yaegashi, N; Yokoyama, Y; Yoshikawa, H | 1 |
| Chisaki, Y; Nakamura, N; Yano, Y | 1 |
| Gress, TM; Rinke, A | 1 |
| Behera, D; Sharma, S; Singh, A; Singh, N | 1 |
| Bueno, R; Catalano, PJ; Enzinger, PC; Hong, TS; King, BL; Mamon, HJ; Martin, NE; Sanford, NN; Wo, JY | 1 |
| Hosomi, Y; Ishii, M; Kato, T; Masuda, N; Minato, K; Misumi, Y; Miura, Y; Nagamata, M; Naoki, K; Ogura, T; Okamoto, H; Okuma, Y; Otani, S; Sasaki, J; Sata, M; Shimokawa, T; Takakura, A; Takata, S; Watanabe, K; Yokoyama, T | 1 |
| Han, D; Li, S; Ren, X; Shang, W; Sun, L; Wang, G; Xu, L | 1 |
| Fukui, T; Igawa, S; Katagiri, M; Kubota, M; Kurahayashi, S; Mitsufuji, H; Naoki, K; Nishinarita, N; Okuma, Y; Ono, T; Ozawa, T; Sasaki, J; Shirasawa, M; Sone, H; Sugimoto, A; Sugita, K | 1 |
| Azuma, K; Hoshino, T; Imamura, Y; Ishii, H; Kinoshita, T; Matsuo, N; Naito, Y; Tokito, T; Yamada, K | 1 |
| Bahl, C; Behera, D; Sharma, S; Singh, N | 1 |
| Nazha, B; Owonikoko, TK | 1 |
| Boudreaux, JP; Ramirez, RA; Thiagarajan, R; Thomas, KEH; Voros, BA; Woltering, EA | 1 |
| Anderson, CD; Burton, EC; Chakravarti, A; Chesnick, HM; King, PD; Lehman, NL; Li, X; McElroy, JP; Mifsud, CS; Sak, M; Usubalieva, A; Zumbar, CT | 1 |
| Auerbach, C; Cheron, R; Natarajan, E; Pashankar, F | 1 |
| De Petris, L; Fang, F; Lewensohn, R; Pettersson, A; Tendler, S; Viktorsson, K; Zhan, Y | 1 |
| Amrahli, M; Cressey, P; Gedroyc, W; So, PW; Thanou, M; Wright, M | 1 |
| Bargh-Dawson, H; Brown, E; Gerrard, J; Hughes, AM; Jones, GN; Lau, A; O'Connor, MJ; Odedra, R; Wallez, Y; Wijnhoven, PWG; Wilson, Z; Young, LA | 1 |
| Hamada, M; Ichikawa, D; Imaya, M; Kawashima, N; Kojima, S; Miwata, S; Muramatsu, H; Narita, A; Narita, K; Nishikawa, E; Nishio, N; Takahashi, Y; Wakamatsu, M; Yamamori, A; Yoshida, T | 1 |
| Min, S; Zheng, Q; Zhou, Y | 1 |
| Bonnabry, P; Fleury-Souverain, S; Guillarme, D; Maurin, J; Rudaz, S | 1 |
| Huang, Z; Zhang, Y | 1 |
| Kashu, N; Kataoka, N; Makimoto, S; Mushiake, Y; Shintani, H; Takami, T; Yamaguchi, T; Yasuda, K | 1 |
| Hiramatsu, H; Iwai, A; Kato, I; Kobushi, H; Kozuki, K; Kubota, H; Obu, S; Saida, S; Takita, J; Tanaka, K; Tasaka, K; Uchihara, Y; Umeda, K | 1 |
33 review(s) available for irinotecan and carboplatin
| Article | Year |
|---|---|
Experience with new chemotherapeutic agents in non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Treatment Outcome | 1998 |
[Irinotecan-containing combinations in solid tumors, except colonic carcinomas].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diarrhea; Docetaxel; Enzyme Inhibitors; Etoposide; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
Chemotherapy in metastatic non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Mitomycin; Paclitaxel; Taxoids; Tirapazamine; Triazines; Vinblastine; Vinorelbine | 2000 |
Chemoradiation in locally advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Forecasting; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Lung cancer: therapeutic options for stage IV and recurrent NSCLC.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
[Platinum compounds in cancer therapy--past, present, and future].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Forecasting; Humans; Irinotecan; Medical Oncology; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Platinum | 2001 |
Rationale for non-platinum chemotherapy in advanced NSCLC.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2001 |
Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2001 |
Radiosensitization with chemotherapeutic agents.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Platinum Compounds; Radiation-Sensitizing Agents; Taxoids; Vinblastine; Vinorelbine | 2001 |
Brief communication: use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pemetrexed; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Urogenital Neoplasms | 2002 |
[Current status of the chemotherapy for lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate; Taxoids | 2002 |
Complete response to radiation therapy in a patient with chemotherapy-resistant ovarian clear cell adenocarcinoma.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Drug Resistance; Female; Humans; Irinotecan; Magnetic Resonance Imaging; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retreatment | 2002 |
Phase I. Trial of irinotecan plus carboplatin in two dose schedules.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
[The guidelines for diagnostics and treatment of cervical cancer].
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hysterectomy; Ifosfamide; Irinotecan; Lymph Node Excision; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Palliative Care; Practice Guidelines as Topic; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Time Factors; Uterine Cervical Neoplasms | 2004 |
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Endosonography; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Irinotecan; Life Tables; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Preoperative Care; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Radiotherapy, Adjuvant; Retrospective Studies; Sensitivity and Specificity; Survival Analysis; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2004 |
[Irinotecan hydrochloride (CPT-11) for advanced cervical cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Irinotecan; Mitomycin; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Topoisomerase I Inhibitors; Treatment Outcome; Uterine Cervical Neoplasms | 2004 |
[Second-line chemotherapy for recurrent ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Platinum; Taxoids | 2005 |
Chemoresistance in non-small cell lung cancer.
Topics: Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Tubulin; Vinblastine; Vinorelbine | 2005 |
Docetaxel in the management of advanced pancreatic cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Taxoids; Thalidomide | 2005 |
Evolving role of irinotecan in small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Screening Assays, Antitumor; Humans; Irinotecan; Lung Neoplasms | 2003 |
[Lung carcinoma].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Quality of Life; Vinblastine; Vinorelbine | 2006 |
[Lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Etoposide; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Pemetrexed; Taxoids | 2007 |
[Chemotherapy in lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate | 2007 |
A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Etoposide; Humans; Irinotecan; Lung Neoplasms; Randomized Controlled Trials as Topic | 2010 |
An updated meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Rate | 2012 |
[Carboplatin plus irinotecan induced partial response in a patient with small cell carcinoma of the prostate; a case report].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carboplatin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Creutzfeldt-Jakob Syndrome; Fatal Outcome; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Phosphopyruvate Hydratase; Prostate; Prostatic Neoplasms; Transurethral Resection of Prostate; Treatment Outcome | 2014 |
[Peritoneal tumor pathology - case no. 3 : peritoneal well-differentiated papillary mesothelioma].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carboplatin; Combined Modality Therapy; Cystadenofibroma; Diagnosis, Differential; Female; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Leucovorin; Mesothelioma; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Organoplatinum Compounds; Ovarian Neoplasms; Ovariectomy; Oxaliplatin; Paclitaxel; Pemetrexed; Peritoneal Neoplasms | 2015 |
[First-line Chemotherapy for Extensive-disease Small Cell Lung Cancer:
A Network Meta-analysis].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Network Meta-Analysis; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma | 2016 |
Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Etoposide; Gastrointestinal Neoplasms; Humans; Irinotecan; Ki-67 Antigen; Neoplasm Grading; Neuroendocrine Tumors; Practice Guidelines as Topic; Prognosis; Treatment Outcome | 2017 |
Comparison of irinotecan/platinum versus etoposide/platinum chemotherapy for extensive-stage small cell lung cancer: A meta-analysis.
Topics: Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Diarrhea; Etoposide; Fatigue; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Nausea; Neoplasm Staging; Neutropenia; Odds Ratio; Proportional Hazards Models; Small Cell Lung Carcinoma; Thrombocytopenia; Vomiting | 2017 |
Current Treatment Options in Gastroenteropancreatic Neuroendocrine Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Clinical Trials as Topic; Etoposide; Humans; Intestinal Neoplasms; Irinotecan; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Radiopharmaceuticals; Stomach Neoplasms | 2019 |
A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Etoposide; Humans; Irinotecan; Lung Neoplasms; Network Meta-Analysis; Paclitaxel; Pemetrexed; Vinorelbine | 2022 |
[A Case of Long-Term Remission with Surgical Therapy and Chemoradiotherapy for a Rapidly Increasing Large Cell Neuroendocrine Carcinoma(LCNEC)].
Topics: Adult; Carboplatin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Chemoradiotherapy; Cisplatin; Humans; Irinotecan; Lung; Lung Neoplasms; Male | 2023 |
90 trial(s) available for irinotecan and carboplatin
| Article | Year |
|---|---|
Combination phase I/II study of irinotecan hydrochloride (CPT-11) and carboplatin in relapsed or refractory non-Hodgkin's lymphoma. CPT-11/Lymphoma Study Group.
Topics: Abdominal Pain; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Vomiting | 1996 |
A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins | 1998 |
Induction of gamma-glutamylcysteine synthetase gene expression by platinum drugs in peripheral mononuclear cells of lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Blotting, Northern; Camptothecin; Carboplatin; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression; Glutamate-Cysteine Ligase; Humans; Irinotecan; Leukocytes, Mononuclear; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Polymerase Chain Reaction; RNA, Messenger; Statistics, Nonparametric; Tumor Cells, Cultured | 1999 |
Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasms; Prospective Studies | 1999 |
[Combination chemotherapy with irinotecan hydrochloride plus carboplatin for patients with advanced or recurrent colorectal cancer--a pilot study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Colorectal Neoplasms; Drug Administration Schedule; Feasibility Studies; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Survival Analysis | 2000 |
Phase I/II trial of irinotecan, carboplatin, and paclitaxel in advanced or metastatic NSCLC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Survival Analysis | 2000 |
Phase I/II study of weekly irinotecan and paclitaxel in patients with SCLC.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Humans; Irinotecan; Lung Neoplasms; Paclitaxel | 2000 |
Phase I study of carboplatin, docetaxel and irinotecan with recombinant human granulocyte colony stimulating factor support in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 2000 |
Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel | 2001 |
Dose escalation study of irinotecan combined with carboplatin for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2001 |
Phase I/II and pharmacologic study of irinotecan and carboplatin for patients with lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Treatment Outcome | 2001 |
Chronotherapy of colorectal cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chronotherapy; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Mice; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Rats | 2002 |
Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dexamethasone; Docetaxel; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Phase I study of carboplatin, irinotecan and docetaxel on a divided schedule with recombinant human granulocyte colony stimulating factor support in patients with stage IIIB or IV non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Recombinant Proteins; Taxoids | 2002 |
Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival; Thrombocytopenia | 2002 |
Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Paclitaxel; Survival Analysis; Vomiting | 2002 |
Phase II study of irinotecan and carboplatin for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Rate; Treatment Outcome | 2002 |
Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2003 |
Toxicity associated with carboplatin/paclitaxel/Irinotecan use in advanced ovarian cancer: preliminary analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Women's Health | 2003 |
Phase I. Trial of irinotecan plus carboplatin in two dose schedules.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
Population-based maximum tolerated dose of irinotecan and carboplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2003 |
Irinotecan and carboplatin in metastatic or recurrent non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2003 |
Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2004 |
Phase I study of the combination of irinotecan hydrochloride, carboplatin, and dexamethasone for the treatment of relapsed or refractory malignant lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Dexamethasone; Female; Humans; Irinotecan; Lymphoma; Male; Maximum Tolerated Dose; Middle Aged; Salvage Therapy; Treatment Outcome | 2004 |
Phase I dose escalation study of carboplatin to a fixed dose of irinotecan as first-line treatment of small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neutropenia; Radiography; Thrombocytopenia; Treatment Outcome | 2004 |
Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Rate; Thrombocytopenia | 2004 |
Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Conformal; Remission Induction; Survival Analysis; Treatment Outcome | 2004 |
Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Treatment Outcome | 2004 |
Combination chemotherapy with irinotecan hydrochloride (CPT-11) and mitomycin C in platinum-refractory ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Mitomycin; Ovarian Neoplasms; Pilot Projects | 2004 |
Irinotecan and carboplatin in metastatic or recurrent NSCLC: an update.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Survival Analysis; Treatment Outcome | 2004 |
[Feasibility survey (Phase I-II) of a four drugs combination (5-fluorouracil, folinic acid, carboplatin and irinotecan) delivered using a chronomodulated infusion in the treatment of advanced colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chronobiology Phenomena; Cohort Studies; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged | 2005 |
A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Female; Humans; Irinotecan; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms | 2005 |
SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Carcinoma; Disease Progression; Docetaxel; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2006 |
Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Irinotecan; Italy; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Taxoids; Treatment Outcome | 2006 |
Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease Progression; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2006 |
A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Prospective Studies; Recombinant Proteins; Survival Analysis; Treatment Outcome | 2006 |
Influence of low-energy laser in the prevention of oral mucositis in children with cancer receiving chemotherapy.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Child; Child, Preschool; Cohort Studies; Etoposide; Female; Humans; Ifosfamide; Irinotecan; Low-Level Light Therapy; Male; Methotrexate; Mouth Mucosa; Neoplasms; Nutritional Status; Oral Hygiene; Severity of Illness Index; Stomatitis; Treatment Outcome | 2007 |
Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Thalidomide; Treatment Outcome | 2006 |
A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2006 |
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Quality of Life; Survival Rate; Vinblastine; Vinorelbine | 2007 |
Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small cell and neuroendocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms | 2007 |
Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Rate; Thalidomide | 2006 |
A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pharmacogenetics; Probability; Survival Analysis; Treatment Outcome | 2006 |
A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Analysis; Treatment Outcome | 2007 |
Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Radiation-Sensitizing Agents; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome; Virginia | 2007 |
Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis | 2008 |
Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Salvage Therapy; Survival Analysis; Topotecan | 2008 |
Chemotherapy for brain metastases in small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cranial Irradiation; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2008 |
Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small ce
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Contraindications; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonectomy; Quinazolines; Radiation-Sensitizing Agents; Radiotherapy, Conformal; Retrospective Studies; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Prognosis; Survival Analysis | 2008 |
Irinotecan plus carboplatin for patients with carcinoma of unknown primary site.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms, Unknown Primary; Survival Rate | 2009 |
Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Child; Child, Preschool; Female; Humans; Infant; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms | 2009 |
Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Survival Rate | 2009 |
A landmark point analysis with cytotoxic agents for advanced NSCLC.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Prognosis; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2009 |
A phase II study of cisplatin and irinotecan as induction chemotherapy followed by accelerated hyperfractionated thoracic radiotherapy with daily low-dose carboplatin in unresectable stage III non-small cell lung cancer: JCOG 9510.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Remission Induction; Treatment Outcome | 2009 |
Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Camptothecin; Carboplatin; Female; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome | 2009 |
Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2010 |
Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Camptothecin; Carboplatin; Disease Progression; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma; Treatment Outcome | 2011 |
Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Feasibility Studies; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Treatment Outcome | 2010 |
Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mitomycin; Paclitaxel; Radiotherapy, Adjuvant; Vindesine | 2010 |
Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Treatment Outcome; Young Adult | 2010 |
Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carboplatin; Cohort Studies; Combined Modality Therapy; Dacarbazine; Dexamethasone; Drug Administration Schedule; Female; Glioma; Glucocorticoids; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Prospective Studies; Quinazolines; Radiosurgery; Radiotherapy Dosage; Temozolomide; Tumor Burden; Vincristine; Young Adult | 2012 |
Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Deoxycytidine; Docetaxel; Endostatins; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Recombinant Proteins; Survival Rate; Taxoids; Treatment Outcome | 2010 |
A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease-Free Survival; Etoposide; Female; Germany; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma | 2011 |
Phase II trial of the combination of carboplatin and irinotecan in elderly patients with small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease-Free Survival; Female; Humans; Irinotecan; Lung Neoplasms; Male; Medical Oncology; Safety; Small Cell Lung Carcinoma; Time Factors; Treatment Outcome | 2011 |
Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carboplatin; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local | 2011 |
A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma | 2011 |
Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carboplatin; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Treatment Outcome | 2012 |
A weekly combination of carboplatin and irinotecan for previously untreated extensive disease small-cell lung cancer, results of a minimum follow-up of 3 years: a multi-center Phase II trial JMTO LC02-02.
Topics: Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Survival Analysis; Treatment Outcome | 2012 |
Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease Progression; Female; Humans; Indoles; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Treatment Outcome | 2012 |
Concurrent radiation with irinotecan and carboplatin in intermediate- and high-risk rhabdomyosarcoma: a report on toxicity and efficacy from a prospective pilot phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemoradiotherapy; Child; Female; Humans; Irinotecan; Male; Pilot Projects; Rhabdomyosarcoma; Soft Tissue Neoplasms | 2013 |
A phase I clinical trial of irinotecan and carboplatin in patients with extensive stage small cell lung cancer.
Topics: Adult; Antineoplastic Agents; Area Under Curve; Camptothecin; Carboplatin; Diarrhea; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Sepsis; Small Cell Lung Carcinoma; Thrombosis | 2012 |
Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensive-stage small-cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Severity of Illness Index; Small Cell Lung Carcinoma; Thrombocytopenia; Treatment Outcome | 2012 |
Phase I - II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Colorectal Neoplasms; Disease Progression; Drug Chronotherapy; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Treatment Outcome | 2013 |
Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemoradiotherapy; Cisplatin; Confidence Intervals; Dehydration; Disease-Free Survival; Dose Fractionation, Radiation; Esophagitis; Etoposide; Female; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Small Cell Lung Carcinoma | 2013 |
Phase II study of carboplatin and weekly irinotecan combination chemotherapy in recurrent ovarian cancer: a Kansai clinical oncology group study (KCOG0330).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms | 2013 |
Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 2013 |
A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Camptothecin; Carboplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Endometrial Neoplasms; Female; Granisetron; Humans; Irinotecan; Logistic Models; Middle Aged; Morpholines; Neoplasms; Ovarian Neoplasms; Temperance; Treatment Outcome; Vomiting | 2013 |
A phase II study of combination chemotherapy using docetaxel and irinotecan for TC-refractory or TC-resistant ovarian carcinomas (GOGO-OV2 study) and for primary clear or mucinous ovarian carcinomas (GOGO-OV3 Study).
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Japan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Taxoids | 2013 |
A feasibility study of carboplatin plus irinotecan treatment for elderly patients with extensive disease small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Magnetic Resonance Imaging; Male; Neoplasm Staging; Prospective Studies; Radiotherapy, Adjuvant; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2014 |
A Phase II/III study comparing carboplatin and irinotecan with carboplatin and etoposide for the treatment of elderly patients with extensive-disease small-cell lung cancer (JCOG1201).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Patient Selection; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2015 |
Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retreatment; Small Cell Lung Carcinoma; Survival Rate | 2015 |
Weekly irinotecan combined with carboplatin for patients with small-cell lung cancer: A phase I study.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Diarrhea; Feasibility Studies; Febrile Neutropenia; Female; Humans; Hypokalemia; Hyponatremia; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Small Cell Lung Carcinoma; Thrombocytopenia; Time Factors; Treatment Outcome; Vomiting | 2015 |
Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Brain Diseases, Metabolic; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Administration Schedule; Endonucleases; Etoposide; Fatigue; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mitosis; Multiple Organ Failure; Pneumonia; Treatment Outcome; Weight Loss | 2015 |
Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Disease-Free Survival; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Survival Rate | 2016 |
Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemoradiotherapy; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Small Cell Lung Carcinoma | 2017 |
Treatment patterns and survival outcomes for small-cell lung cancer patients - a Swedish single center cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Sweden; Treatment Outcome | 2020 |
81 other study(ies) available for irinotecan and carboplatin
| Article | Year |
|---|---|
[Combination therapy with irinotecan and CBDCA for patients in terminal stage of ovarian carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cystadenocarcinoma, Serous; Drug Administration Schedule; Female; Humans; Irinotecan; Leukopenia; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Thrombocytopenia | 1996 |
Antitumor effect of CPT-11, a camptothecin derivative, on human testicular tumor xenografts in nude mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Organoplatinum Compounds; Teratocarcinoma; Testicular Neoplasms; Topoisomerase I Inhibitors; Transplantation, Heterologous; Vinblastine | 1997 |
[A case of papillary adenocarcinoma of the ovary that responded favorably to irinotecan hydrochloride and cisplatin after the administration of paclitaxel and carboplatin].
Topics: Adenocarcinoma, Papillary; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carboplatin; Cisplatin; Cyclophosphamide; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2001 |
[Globalization of anti-cancer therapies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Cisplatin; Colorectal Neoplasms; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Stomach Neoplasms | 2002 |
Influence of phenytoin on the disposition of irinotecan: a case report.
Topics: Adolescent; Anticonvulsants; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Camptothecin; Carboplatin; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexamethasone; Disease Progression; Drug Interactions; Enzyme Induction; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Irinotecan; Male; Melphalan; Mixed Function Oxygenases; Neoplasm Recurrence, Local; Ondansetron; Phenobarbital; Phenytoin; Pineal Gland; Pinealoma; Prodrugs; Salvage Therapy; Seizures | 2002 |
Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Thorax; Treatment Failure | 2002 |
Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Camptothecin; Carboplatin; Carmustine; Drug Synergism; Genetic Therapy; Glioma; Humans; I-kappa B Proteins; Irinotecan; NF-kappa B; NF-KappaB Inhibitor alpha; Repressor Proteins; Transcriptional Activation; Transfection; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2003 |
Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Cyclophosphamide; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Retrospective Studies | 2003 |
[The platelet-sparing effect of carboplatin and docetaxel combination chemotherapy for lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Docetaxel; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Platelet Count; Taxoids; Thrombopoietin | 2003 |
Drug sensitivity-related benefit of systematic lymphadenectomy during cytoreductive surgery in optimally debulked stages IIIc and IV ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Irinotecan; Lymph Node Excision; Middle Aged; Multivariate Analysis; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 2004 |
[Clinical pathway based on evidence-based medicine (EBM) for chemotherapy for lung cancer].
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Critical Pathways; Etoposide; Evidence-Based Medicine; Female; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Vomiting | 2004 |
Combined systemic chronotherapy and hepatic artery infusion for the treatment of metastatic colorectal cancer confined to the liver.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chronotherapy; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Quality of Life | 2005 |
A long-term survival case of small cell lung cancer in an HIV-infected patient.
Topics: Alkynes; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Benzoxazines; Camptothecin; Carbamates; Carboplatin; Carcinoma, Small Cell; Cisplatin; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Administration Schedule; Furans; HIV Infections; HIV Long-Term Survivors; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Oxazines; Ritonavir; Sulfonamides; Tomography, X-Ray Computed | 2005 |
[Favorable response obtained by low dose chemotherapy in an elderly patient with extensive small cell lung cancer and renal dysfunction].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Humans; Irinotecan; Kidney Diseases; Lung Neoplasms; Male | 2005 |
[Surgical treatment for locally advanced lung cancer; therapeutic response of induction chemotherapy and postoperative chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumonectomy; Postoperative Period; Survival Rate | 2005 |
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Camptothecin; Carboplatin; Drug Therapy, Combination; Etoposide; Female; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Vascular Endothelial Growth Factor A | 2006 |
Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Cytarabine; Depsipeptides; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Imatinib Mesylate; Irinotecan; K562 Cells; Leukemia; Lymphoma; Mercaptopurine; Piperazines; Pyrimidines; Time Factors | 2007 |
[Lung cancer with bone metastasis].
Topics: Analgesics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Diphosphonates; Docetaxel; Drug Administration Schedule; Etoposide; Fractures, Bone; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Pain, Intractable; Prognosis; Quinazolines; Radiotherapy Dosage; Taxoids | 2006 |
[Outpatient chemotherapy in gynecologic oncology].
Topics: Ambulatory Care Facilities; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Combined Modality Therapy; Doxorubicin; Drug Administration Schedule; Female; Humans; Irinotecan; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Uterine Cervical Neoplasms; Uterine Neoplasms | 2006 |
Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Analysis | 2007 |
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Body Mass Index; Body Size; Body Surface Area; Body Weight; Camptothecin; Carboplatin; Cisplatin; Cytosine; Dioxolanes; Docetaxel; Doxorubicin; Humans; Irinotecan; Metabolic Clearance Rate; Obesity; Paclitaxel; Taxoids; Topotecan | 2007 |
Carbon beam therapy in recurrent ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbon; Carboplatin; Carcinoma, Endometrioid; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Hysterectomy; Irinotecan; Lymph Node Excision; Neoplasm Recurrence, Local; Omentum; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Radiotherapy, High-Energy; Remission Induction; Salvage Therapy | 2008 |
[Carboplatin and CPT-11 chemotherapy in a hemodialysis patient with small-cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Female; Humans; Irinotecan; Renal Dialysis; Tomography, X-Ray Computed | 2007 |
Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis.
Topics: Administration, Oral; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Cost-Benefit Analysis; Cyclophosphamide; Doxorubicin; Etoposide; Female; Health Care Costs; Humans; Infusions, Intravenous; Insurance Claim Review; Irinotecan; Male; Middle Aged; Retrospective Studies; Topotecan; United States; Vincristine | 2008 |
Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Down-Regulation; Drug Synergism; Female; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor Binding Proteins; Irinotecan; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Proto-Oncogene Proteins c-akt; Recombinant Proteins; Signal Transduction; Transplantation, Heterologous | 2008 |
Primary small cell carcinoma of the breast.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Carcinoma, Small Cell; Etoposide; Fatal Outcome; Female; Humans; Irinotecan; Liver Neoplasms; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Thoracic Wall | 2009 |
Bortezomib as a therapeutic candidate for neuroblastoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Boronic Acids; Bortezomib; Brain Neoplasms; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Survival; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Genes, p53; Humans; Irinotecan; Neuroblastoma; NF-kappa B; Pyrazines | 2008 |
Chemotherapy: Irinotecan or etoposide as front-line therapy for SCLC?
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase III as Topic; Diarrhea; Drug Therapy; Drug Therapy, Combination; Enzyme Inhibitors; Ethnicity; Etoposide; Female; Follow-Up Studies; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Neutropenia; Polymorphism, Genetic; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Analysis; Therapeutic Equivalency; Time Factors; Treatment Outcome | 2009 |
Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate | 2010 |
Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a patient with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carboplatin; Carcinoma, Small Cell; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Meningeal Carcinomatosis; Neoplasm Recurrence, Local; Peptide Fragments; Prostatic Neoplasms; Recombinant Proteins; Spinal Puncture; Treatment Outcome | 2009 |
Small cell carcinoma of the breast.
Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Carcinoma, Small Cell; Female; Humans; Irinotecan; Neoplasm Recurrence, Local; Radiotherapy Dosage; Radiotherapy, Adjuvant | 2009 |
Cytokeratin expression patterns in multiple infundibulocystic basal cell carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carboplatin; Carcinoma, Basal Cell; Docetaxel; Female; Humans; Immunohistochemistry; Irinotecan; Keratins; Lung Neoplasms; Neoplasms, Second Primary; Skin Neoplasms; Taxoids | 2011 |
[Chemotherapy-induced myelosuppression and treatment efficacy in extensive-stage small cell lung cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Carboplatin; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma | 2009 |
[A case of small cell lung cancer (extensive disease) with liver metastasis acquiring stable disease by hepatic arterial infusion chemotherapy].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Small Cell Lung Carcinoma | 2010 |
Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carboplatin; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Temozolomide | 2011 |
Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Endonucleases; Etoposide; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis | 2011 |
Expression of phosphorylated Akt in patients with small cell carcinoma of the lung indicates good prognosis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Immunohistochemistry; Irinotecan; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Middle Aged; Phosphorylation; Polymorphism, Genetic; Prognosis; Proto-Oncogene Proteins c-akt; Small Cell Lung Carcinoma; Treatment Outcome | 2010 |
High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Child; Child, Preschool; Cohort Studies; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Infant; Infant, Newborn; Irinotecan; Male; Neuroblastoma; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Temozolomide; Topotecan; Treatment Outcome | 2011 |
Infratentorial brain metastases of pediatric non-epithelial malignant tumors: three case reports.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Dactinomycin; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant; Infratentorial Neoplasms; Irinotecan; Melphalan; Neoplasm Metastasis; Neuroblastoma; Rhabdomyosarcoma; Thiotepa; Topotecan; Vincristine | 2011 |
Second-line chemotherapy in patients with primary unknown cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Risk Factors; Taxoids; Time Factors; Treatment Failure; Treatment Outcome | 2011 |
Impact of induction chemotherapy on estimated risk of radiation pneumonitis in small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation Pneumonitis; Radiotherapy, Conformal; Retrospective Studies; Risk Assessment; Small Cell Lung Carcinoma; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Five hundred patients with Merkel cell carcinoma evaluated at a single institution.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Merkel Cell; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Infusion Pumps; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Research Design; Skin Neoplasms; Treatment Outcome | 2011 |
In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cetuximab; Docetaxel; ErbB Receptors; Genes, ras; Humans; Irinotecan; Male; Mice; Mice, Nude; Mutation; Proto-Oncogene Proteins B-raf; Stomach Neoplasms; Taxoids; Xenograft Model Antitumor Assays | 2012 |
Second-line chemotherapy for carboplatin/paclitaxel-refractory ovarian cancer: are multi-agent chemotherapies of little value truly?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2011 |
Epidermal growth factor receptor mutations in small cell lung cancer patients who received surgical resection in China.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; China; Combined Modality Therapy; Cranial Irradiation; Docetaxel; Endostatins; Exons; Female; Genes, erbB-1; Humans; Incidental Findings; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasms, Multiple Primary; Pneumonectomy; Recombinant Proteins; Smoking; Taxoids; Young Adult | 2012 |
Hypoxia-inducible factor-1α and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Brain Neoplasms; Camptothecin; Carboplatin; Cisplatin; DNA-Binding Proteins; Endonucleases; Etoposide; Female; Follow-Up Studies; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoenzyme Techniques; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2012 |
Adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: an analysis of fully staged patients.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Female; Follow-Up Studies; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Postoperative Care; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2012 |
HADHA is a potential predictor of response to platinum-based chemotherapy for lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Electrophoresis, Gel, Two-Dimensional; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Mitochondrial Trifunctional Protein; Mitochondrial Trifunctional Protein, alpha Subunit; Multienzyme Complexes; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Small Cell Lung Carcinoma; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured | 2011 |
Normal serum CA125 half-life and normal serum nadir CA125 level in patients with ovarian cancers.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Etoposide; Female; Half-Life; Humans; Irinotecan; Linear Models; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Reference Values; Remission Induction; Taxoids | 2012 |
5-day/5-drug myeloablative outpatient regimen for resistant neuroblastoma.
Topics: 3-Iodobenzylguanidine; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Irinotecan; Male; Neuroblastoma; Outpatients; Radionuclide Imaging; Radiopharmaceuticals; Retrospective Studies; Salvage Therapy; Temozolomide | 2013 |
Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Cohort Studies; Etoposide; Female; Humans; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Small Cell Lung Carcinoma; Time Factors; Topotecan; Treatment Outcome | 2015 |
Taxane-sensitivity of ovarian carcinomas previously treated with paclitaxel and carboplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Taxoids | 2013 |
Long-term survival of a patient with extensive small cell carcinoma of unknown primary etiology complicated by nephrotic syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Cranial Irradiation; Edema; Etoposide; Glomerulonephritis, Membranous; Humans; Irinotecan; Lymphatic Metastasis; Neoplasms, Unknown Primary; Nephrotic Syndrome; Paraneoplastic Syndromes; Pleural Effusion, Malignant; Proteinuria; Radiotherapy, Adjuvant; Remission Induction; Tomography, X-Ray Computed | 2014 |
Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Folic Acid; HeLa Cells; Humans; Irinotecan; Mice, Inbred BALB C; Mice, Inbred DBA; Mice, Nude; Neoplasms; Neoplasms, Experimental; Paclitaxel; Taxoids; Topotecan; Treatment Outcome; Vinca Alkaloids; Xenograft Model Antitumor Assays | 2014 |
Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Hospitalization; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Registries; Retrospective Studies; Survival Rate; Taxoids; United States; United States Department of Veterans Affairs; Vinblastine; Vinorelbine | 2014 |
UGT1A1 *6 polymorphism predicts outcome in elderly patients with relapsed or refractory diffuse large B-cell lymphoma treated with carboplatin, dexamethasone, etoposide and irinotecan.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Dexamethasone; Etoposide; Female; Follow-Up Studies; Glucuronosyltransferase; Humans; Irinotecan; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Polymorphism, Genetic; Prospective Studies; Recurrence; Treatment Outcome | 2015 |
A predictive model for evaluating responsiveness to pemetrexed treatment in patients with advanced colorectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carboplatin; Cisplatin; Colorectal Neoplasms; Cyclobutanes; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Logistic Models; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Prognosis | 2014 |
Adjuvant chemotherapy in patients with completely resected small cell lung cancer: a retrospective analysis of 26 consecutive cases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2014 |
ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer.
Topics: Adenocarcinoma, Clear Cell; Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Ifosfamide; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Predictive Value of Tests; Sensitivity and Specificity; Taxoids | 2014 |
A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Capecitabine; Carboplatin; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Trastuzumab | 2014 |
Case of pure ovarian squamous cell carcinoma resistant to combination chemotherapy with paclitaxel and carboplatin but responsive to monotherapy with weekly irinotecan.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Retreatment; Treatment Outcome | 2015 |
Chemoradiation for High-grade Neuroendocrine Carcinoma of the Rectum and Anal Canal.
Topics: Adult; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Camptothecin; Capecitabine; Carboplatin; Carcinoma, Neuroendocrine; Chemoradiotherapy; Cisplatin; Consolidation Chemotherapy; Diarrhea; Digestive System Surgical Procedures; Disease-Free Survival; Etoposide; Female; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Pelvis; Radiation Injuries; Radiodermatitis; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Rectal Neoplasms; Rectum; Retrospective Studies; Survival Rate; Tumor Burden | 2017 |
Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate; Vinblastine; Vinorelbine | 2016 |
The optimal regimen of bevacizumab for recurrent glioblastoma: does dose matter?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carboplatin; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of High-Grade Glioma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bevacizumab; Brain Neoplasms; Camptothecin; Carboplatin; Chemoradiotherapy; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Cyclophosphamide; Dacarbazine; Glioblastoma; Humans; Irinotecan; Lomustine; Neoplasm Grading; Neoplasm Recurrence, Local; Oligodendroglioma; Procarbazine; Radiotherapy; Singapore; Temozolomide; Teniposide; Vincristine | 2015 |
A Novel HSP90 Inhibitor-Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carboplatin; Cell Cycle Checkpoints; Cell Line, Tumor; DNA Damage; Drug Delivery Systems; Drug Synergism; Female; HSP90 Heat-Shock Proteins; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, SCID; Resorcinols; Signal Transduction; Small Cell Lung Carcinoma; Xenograft Model Antitumor Assays | 2016 |
Time-Series Modeling and Simulation for Comparative Cost-Effective Analysis in Cancer Chemotherapy: An Application to Platinum-Based Regimens for Advanced Non-small Cell Lung Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Computer Simulation; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Models, Economic; Paclitaxel; Quality-Adjusted Life Years; Vinblastine; Vinorelbine | 2017 |
Polymorphism in XRCC1 gene modulates survival and clinical outcomes of advanced North Indian lung cancer patients treated with platinum-based doublet chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; DNA-Binding Proteins; Docetaxel; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Polymorphism, Single Nucleotide; Survival Rate; Taxoids; Treatment Outcome; X-ray Repair Cross Complementing Protein 1 | 2017 |
A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Patient Readmission; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Young Adult | 2017 |
Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
Topics: Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Disease-Free Survival; Etoposide; Female; Health Status; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Thrombocytopenia | 2018 |
Rechallenge treatment with a platinum-based regimen in patients with sensitive relapsed small-cell lung cancer.
Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Paclitaxel; Recurrence; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2018 |
Genetic Variants in the Wingless Antagonist Genes (
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axin Protein; Carboplatin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Epistasis, Genetic; Female; Gemcitabine; Genetic Variation; Genotype; Humans; India; Intercellular Signaling Peptides and Proteins; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Pemetrexed; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Smoking; Wnt Proteins | 2018 |
The clinical conundrum of managing relapsed small cell lung cancer.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Carboplatin; Clinical Decision-Making; Disease Progression; Etoposide; Humans; Immunoconjugates; Irinotecan; Liver Neoplasms; Lung Neoplasms; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Piperazines; Pyrimidines; Salvage Therapy; Small Cell Lung Carcinoma; Temozolomide; Thiourea; Topotecan | 2019 |
Cytotoxic synergy between alisertib and carboplatin versus alisertib and irinotecan are inversely dependent on MGMT levels in glioblastoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azepines; Carboplatin; DNA Modification Methylases; DNA Repair Enzymes; Drug Synergism; Glioblastoma; Humans; Irinotecan; Pyrimidines; RNA, Small Interfering; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2019 |
Sustained Remission After Maintenance Irinotecan in Patient With Multiply Relapsed Hepatoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Etoposide; Hepatoblastoma; Humans; Ifosfamide; Infant; Irinotecan; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Remission Induction | 2020 |
Image-guided thermosensitive liposomes for focused ultrasound enhanced co-delivery of carboplatin and SN-38 against triple negative breast cancer in mice.
Topics: Animals; Carboplatin; Drug Delivery Systems; Humans; Irinotecan; Liposomes; Mice; Triple Negative Breast Neoplasms | 2021 |
ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.
Topics: Animals; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Carboplatin; Humans; Indoles; Irinotecan; Morpholines; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Sulfoxides; Triple Negative Breast Neoplasms | 2022 |
Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Etoposide; Humans; Irinotecan; Neoplasm Recurrence, Local; Neuroblastoma; Neutropenia; Retrospective Studies | 2022 |
Development and application of a liquid chromatography coupled to mass spectrometry method for the simultaneous determination of 23 antineoplastic drugs at trace levels.
Topics: Antineoplastic Agents; Busulfan; Carboplatin; Chromatography, Liquid; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Docetaxel; Doxorubicin; Epirubicin; Etoposide; Fluorouracil; Ganciclovir; Humans; Idarubicin; Ifosfamide; Irinotecan; Methanol; Methotrexate; Oxaliplatin; Paclitaxel; Pemetrexed; Tandem Mass Spectrometry; Topotecan; Vinblastine; Vincristine; Water | 2022 |
Iris metastasis as resistance mechanism to atezolizumab, carboplatin, and etoposide but responds to additional irinotecan and anlotinib in a small cell lung cancer patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blindness; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Irinotecan; Iris; Lung Neoplasms; Small Cell Lung Carcinoma | 2023 |
High-dose carboplatin-irinotecan-temozolomide is an effective salvage chemotherapy for relapsed or refractory neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Irinotecan; Neoplasm Recurrence, Local; Neuroblastoma; Retrospective Studies; Salvage Therapy; Temozolomide | 2023 |